These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30476419)

  • 1. FDA user-fee bill seen as speeding approvals, but harming smaller firms.
    Kacik A
    Mod Healthc; 2017 Apr; 47(17):11. PubMed ID: 30476419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
    Lee R
    J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994
    [No Abstract]   [Full Text] [Related]  

  • 3. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
    Bierut MB
    Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552
    [No Abstract]   [Full Text] [Related]  

  • 4. Economic Impacts of the Generic Drug User Fee Act Fee Structure.
    Dong K; Boehm G; Zheng Q
    Value Health; 2017 Jun; 20(6):792-798. PubMed ID: 28577697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs.
    Wilmoth DR
    Health Econ; 2015 Dec; 24(12):1651-6. PubMed ID: 25753390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extending the User Fee Approach to Pharmaceuticals.
    Cutler DM
    JAMA; 2018 Oct; 320(15):1525-1526. PubMed ID: 30326113
    [No Abstract]   [Full Text] [Related]  

  • 7. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 8. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D; Chernew M; Smith DG; Fendrick AM
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA proposes higher fees for drug approvals to cover postmarketing surveillance.
    Tanne JH
    BMJ; 2007 Jan; 334(7586):177. PubMed ID: 17255596
    [No Abstract]   [Full Text] [Related]  

  • 10. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 11. User fees and beyond--the FDA Safety and Innovation Act of 2012.
    Kramer DB; Kesselheim AS
    N Engl J Med; 2012 Oct; 367(14):1277-9. PubMed ID: 23034017
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA joins market.
    Gershon D
    Nature; 1993 Jul; 364(6433):93. PubMed ID: 8321293
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA dependence on drug industry.
    Lawson GW
    J Natl Med Assoc; 2005 Jul; 97(7):1039-40. PubMed ID: 16080677
    [No Abstract]   [Full Text] [Related]  

  • 14. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversy still swirls around FDA user fees: since 1992, the prescription drug user fee act and reauthorizations have sped up new drug approvals--but does speed equal safety?
    Ullman K
    Ann Neurol; 2013 Nov; 74(5):A10-1. PubMed ID: 24353218
    [No Abstract]   [Full Text] [Related]  

  • 16. Whatever happened to user fees and the FDA's promise to expedite new drug approvals?
    Gatty B
    Hosp Formul; 1993 Jul; 28(7):656, 655. PubMed ID: 10127048
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA user fees approved.
    Clin Pharm; 1993 Jan; 12(1):3. PubMed ID: 8428431
    [No Abstract]   [Full Text] [Related]  

  • 18. User fees to fund faster reviews.
    Henkel J
    FDA Consum; 1993 Oct; 27(8):19-21. PubMed ID: 10129049
    [No Abstract]   [Full Text] [Related]  

  • 19. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.